Dr. Brenda Gallie, an internationally recognized leader in retinoblastoma genetics, biology and clinical care founded Impact Genetics’ team in 1999. Over the next decade, our clinical tests for retinoblastoma and hereditary hemorrhagic telangiectasia gained the trust of medical specialists around the world because of the quality of our lab work, focused expertise in those diseases and excellent service.
In 2012, Impact Genetics Inc. combined the expertise of Retinoblastoma Solutions, HHT Solutions and Solutions by Sequence into one company. In 2013, Dynacare Medical Laboratories acquired Impact Genetics, helping us to support our expanding mission of providing cost-effective, high quality genetic testing for rare diseases. Dynacare, owned by LabCorp, is one of Canada’s largest and most respected providers of laboratory services. In 2016, Impact Genetics’ tests were listed on the LabCorp test menu, improving US customer access to Impact Genetics tests.
Dr. Gallie’s original team continues with Impact and together with our new partners, we will build Impact’s expanding services with the same care, attention to detail and expertise we are renowned for. Our growing team is committed to providing high quality genetic diagnostics for rare diseases, to as many people as possible.